• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Long-term Quality of Life and Sexual Function After Neoadjuvant Chemotherapy and Radical Surgery for Locally Advanced Cervical Cancer
【24h】

Long-term Quality of Life and Sexual Function After Neoadjuvant Chemotherapy and Radical Surgery for Locally Advanced Cervical Cancer

机译：Long-term Quality of Life and Sexual Function After Neoadjuvant Chemotherapy and Radical Surgery for Locally Advanced Cervical Cancer

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Background: Cervical cancer survivors report the worst quality of life (QoL) among all cancer survivors and this is mainly due to their younger age and the long-term treatment sequelae.& nbsp;Aim: The purpose of this study is to assess the long-term QoL and sexual function of locally advanced cervical cancer (LACC) patients treated with neoadjuvant chemotherapy (NACT) and radical hysterectomy (RH) instead of the standard chemoradiotherapy.& nbsp;Methods: This is a retrospective case-control study including LACC patients (FIGO stage IIB-IVA) treated with the NACT-RH strategy and a control group of healthy women undergoing hysterectomy for uterine fibromatosis in the same period.& nbsp;Outcomes: Main outcome measures were the EORTC QLQ-C30 and EORTC QLQ-CX24 for quality of life and Female Sexual Function Index (FSFI) for sexual function.& nbsp;Results: Overall, 96 patients were included: 48 LACC and 48 controls. The mean age at diagnosis was 45.5 +/- 9.0 and 47.0 +/- 7.8, respectively (P = .38). Compared to controls, LACC patients reported lower mean scores for the global health status (69.4 +/- 22.6 vs 81.2 +/- 24.3; Mean Difference (MD):-11.80 [95% CI:-21.19, -2.41]; P = .016), QLQ-C30 functional scale (80.1 +/- 22.6 vs 92.4 +/- 14.9; MD:-12.30 [95% CI:-19.96, -4.64]; P = .002), QLQ-Cx24 functional scale (55.5 +/- 25.0 vs 80.4 +/- 22.4; MD: -24.00 [95% CI:-34.40, -15.40]; P < .001), and the total FSFI (19.3 +/- 9.6 vs 26.2 +/- 9.9; MD: -6.90 [95% CI:-10.80, -3.00]; P < .001). On the other hand, LACC patients reported higher mean scores on the QLQ-C30 (16.9 +/- 22.1 vs 8.4 +/- 16.6; MD: 8.50 [95% CI: 0.68, 16.32]; P = .03) and QLQ-CX24 (26.0 +/- 28.8 vs 15.0 +/- 11.7; MD: 11.00 [95% CI:-2.21, 19.79]; P = .01) symptoms scales.& nbsp;Clinical implications: The confirmed poor quality of life even in surgically treated LACC survivors underlines the importance of tailoring parametrectomy based on lymph node status and developing personalized strategies.& nbsp;Strengths and limitations: The study assessed the long-term QoL and sexual function in the specific subpopulation of LACC patients treated with NACT-RH. Main limitations include the small sample size and the retrospective design.& nbsp;Conclusion: LACC long-term survivors treated with NACT-RH experience poor QoL and sexual dysfunction.& nbsp;Copyright (C)& nbsp;2022, International Society of Sexual Medicine. Published by Elsevier Inc. All rights reserved.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号